Wenstrup Votes Against Measure that Would Decrease Access to Life-Saving Medicine
Washington, December 12, 2019/UploadedPhotos/HighResolution/4bb6d3ff-025c-482b-94ce-325a50ca789e.jpg
WASHINGTON, D.C. – Today, Congressman Brad Wenstrup (R-OH) released the following statement after voting against H.R. 3, which would stifle medical research, innovation, and patient access to life-saving medicine:
“Americans deserve to have a health care system that delivers treatments when they need it most. The Democrats’ purely partisan legislation limits providers’ and patients’ access to potentially life-saving medicine by crippling American health innovation with government price controls and threats of huge tax increases on health innovators. I am disappointed that Democrats chose to abandon the bipartisan progress we made earlier this year on drug pricing in the Ways and Means Committee in favor of a partisan bill that would do damage to Americans’ access to medicine,” said Congressman Brad Wenstrup, D.P.M.
· Earlier this year, the House Committee on Ways and Means passed the bipartisan Prescription Drug STAR Act, which began addressing prescription drug pricing issues by improving transparency and public reporting of drug prices to help Americans understand the methodology behind pricing.
· Congressman Wenstrup is an original co-sponsor of the alternative drug pricing bill, H.R. 19, which includes over 40 bipartisan provisions to lower out of pocket spending and protect access to new medicines and cures.
# # #